Please assess the completion status of the following clinical trial:

Trial Title: Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age~* Stage 3-5 CKD~* hs-CRP \> 2.0 mg/L~* Comply with contraception~Exclusion Criteria:~* Low neutrophil count~* Low platelet count~* Spot urine protein to creatinine ration \> 4000 mg/g~* ALT/AST \>2.5x ULN~* TSAT \< 10%~* Positive TB test~* Evidence of HIV, hepatitis B~* Blind or illiterate~* Expected to require blood transfusion~* Thromboembolic event within 12-weeks~* Evidence of active infection~* Peptic ulcer disease, diverticulitis, inflammatory bowel disease~* Uncontrolled hypertension~* Planned coronary revascularization~* Major cardiac surgery, CHF~* Active malignancy, bone marrow or organ transplant~* Allergy to study drug~* Treatment with investigational drug, treatment with HIF stabilizer or ESA~* Use of immunosuppressive drugs, systemic antibiotics~* Breastfeeding, any other significant medical history

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo
- Ziltivekimab 7.5 mg (Type: EXPERIMENTAL): None
- Ziltivekimab 15 mg (Type: EXPERIMENTAL): None
- Ziltivekimab 30 mg (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).